Brief: Kiniksa Pharmaceuticals Ltd Says Cash Reserves Of $201 Million Expected To Fund Operations Into At Least 2027

Kiniksa Pharmaceuticals International

31/10/2023 11:38

Oct 31 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA PHARMACEUTICALS LTD - CASH RESERVES OF $201
MILLION
EXPECTED TO FUND OPERATIONS INTO AT LEAST 2027
    * KINIKSA PHARMACEUTICALS LTD - KPL-404 PHASE 2 RHEUMATOID
ARTHRITIS DATA FROM COHORTS 1-3 NOW EXPECTED IN Q1 2024
    * KINIKSA PHARMACEUTICALS LTD - KINIKSA EXPECTS 2023
ARCALYST NET
PRODUCT REVENUE OF BETWEEN $220 MILLION AND $230 MILLION.
    * KINIKSA PHARMACEUTICALS LTD - AS OF SEPTEMBER 30, 2023,
KINIKSA
HAD $201.1 MILLION OF CASH, CASH EQUIVALENTS, AND SHORT-TERM
INVESTMENTS AND NO DEBT

Source text for Eikon:  ID:nGNXbj6lfH 
Further company coverage:  KNSA.O